恩瑞格在22020年进入医保了吗？

(Deferasirox) is very effective. It plays a good auxiliary role in patients with thalassemia or other rare anemias that require long-term blood transfusions that lead to iron accumulation (people who require long-term blood transfusions (blood transfusion volume up to 100 ml/kg) and whose serum ferritin exceeds 1000 μg/L). Today we will learn more about whether Enrig will enter medical insurance in 2020?

In 2010, Enrig (deferasirox) was approved for marketing in China. According to Medical Partner Travel, Enrig (deferasirox) has not been officially included in medical insurance. Enrig India Cipla Desirox 500mg*30 tablets is about 240$. Swiss Novartis Asunra 400mg*30 tablets is around 420$. Patients in need can purchase drugs abroad or obtain drugs through domestic professional overseas medical service organizations (such as Medical Companion Travel), which are guaranteed to be genuine.

Enrig (deferasirox) is easy to administer, significantly reduces ferritin levels, and has a definite effect in protecting important target organ systems such as the liver, heart, and endocrine system. It is currently the preferred option for iron removal treatment.

Enrig (deferasirox) is an iron chelator product developed by the Swiss pharmaceutical company Novartis. It is the first oral iron-depleting agent approved by the U.S. FDA for routine use. It is approved for use in patients ≥2 years old with chronic iron overload caused by blood transfusion. In Europe, it is recommended as a first-line drug for patients with thalassemia iron overload over 6 years old. Clinical research is currently underway in China; Ⅱ , phase III clinical trials and pharmacokinetic studies have shown that it has good safety and tolerability, can significantly reduce the iron load on the heart and liver, and is easily accepted by patients. At the same time, it also has pharmaceutical properties such as antifungal (such as Mucor that grows in an iron-rich environment), anti-cell proliferation, anti-malarial, anti-oxidative stress damage, anti-cytotoxic-induced apoptosis, etc.; it can be used for the treatment of secondary hemochromatosis, porphyria cutanea tarda and other diseases.

Enrig (deferasirox) is a ligand with three protrusions. Although the affinity of Enrig dispersible tablets to zinc and copper is very low, the concentrations of these trace metals in the serum still decreased to varying degrees after administration. The tolerability and safety of Enrige are relatively good among similar drugs. Therefore, patients can also take it for a long time, but it is best to consult a doctor first and use it under the guidance of a doctor to avoid adverse reactions.

The above is the content of (deferasirox) medical insurance, I hope it can help you!

Recommended related hot articles: /newsDetail/80963.html